NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Price Target & More

$40.01 +0.87 (+2.22 %)
(As of 04/25/2018 03:00 AM ET)
Previous Close$39.14
Today's Range$38.90 - $40.25
52-Week Range$11.30 - $45.85
Volume591,700 shs
Average Volume1.24 million shs
Market Capitalization$1.90 billion
P/E Ratio-15.21
Dividend YieldN/A
Beta1.48

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Debt-to-Equity Ratio0.28%
Current Ratio3.89%
Quick Ratio3.89%

Price-To-Earnings

Trailing P/E Ratio-15.21
Forward P/E Ratio-14.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.34 million
Price / Sales89.58
Cash FlowN/A
Price / CashN/A
Book Value$5.28 per share
Price / Book7.58

Profitability

EPS (Most Recent Fiscal Year)($2.63)
Net Income$-91,400,000.00
Net Margins-250.93%
Return on Equity-62.82%
Return on Assets-33.04%

Miscellaneous

Employees159
Outstanding Shares47,780,000

How to Become a New Pot Stock Millionaire

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.30. The biopharmaceutical company earned $15.40 million during the quarter, compared to analyst estimates of $5.75 million. Arena Pharmaceuticals had a negative return on equity of 62.82% and a negative net margin of 250.93%. Arena Pharmaceuticals's revenue was down 77.8% on a year-over-year basis. During the same quarter last year, the business posted $1.60 earnings per share. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

7 analysts have issued 12 month price objectives for Arena Pharmaceuticals' stock. Their predictions range from $44.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $58.00 in the next twelve months. View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)
  • 2. According to Zacks Investment Research, "Arena’s only approved product is Belviq, used for chronic weight management. Though it was the first obesity drug to be approved by the FDA in over a decade, is yet to impress with its performance. However, the company’s partnership agreements and efforts to improve the performance of the drug are impressive. We are also encouraged by the company’s cost-reduction initiatives to streamline the organization to support its development programs. Shares of the company have outperformed the industry in the last one year. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates, still several years from commercialization. Plus, competition remains intense in the obesity market with both branded and generic players. " (3/9/2018)
  • 3. Cantor Fitzgerald analysts commented, "KOL event could fill in some important blank spaces. ARNA will host a lunch event on January 29 (12:30-1:30 pm) in NYC with two physician consultants to discuss modulators of S1P receptors and etrasimod, specifically. We believe the event could be helpful for investors as it relates to understanding important pharmacokinetic and pharmacodynamic properties of the drug candidate that we highlighted in a recent research report (here)." (1/17/2018)

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 3,192,659 shares, an increase of 71.8% from the March 15th total of 1,858,178 shares. Based on an average trading volume of 4,246,081 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the company's shares are sold short.

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Tina Susan Nova Ph.D., Independent Chairman of the Board (Age 63)
  • Amit D. Munshi, President, Chief Executive Officer, Director (Age 49)
  • Kevin R. Lind, Chief Financial Officer, Executive Vice President (Age 41)
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary (Age 52)
  • Vincent Aurentz, Executive Vice President and Chief Business Officer (Age 49)
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer (Age 48)
  • Jennifer Jarrett, Director (Age 46)
  • Scott H. Bice J.D., Independent Director (Age 74)
  • Jayson Dallas M.D., Independent Director (Age 49)
  • Oliver S. Fetzer Ph.D., Independent Director (Age 52)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News headlines about ARNA stock have trended positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 0.35 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.92%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christine Anna White and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $40.01.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $1.90 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arena Pharmaceuticals (NASDAQ:ARNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Arena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $58.00, suggesting that the stock has a possible upside of 44.96%. The high price target for ARNA is $79.00 and the low price target for ARNA is $44.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.882.71
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.00$58.00$41.1429$38.8333
Price Target Upside: 44.96% upside45.91% upside21.44% upside54.78% upside

Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018CitigroupReiterated RatingPositive -> Buy$62.00HighView Rating Details
3/20/2018JMP SecuritiesBoost Price TargetMkt Outperform -> Outperform$63.00 -> $79.00HighView Rating Details
3/20/2018Wells FargoLower Price TargetPositive -> Outperform$53.00 -> $60.00HighView Rating Details
3/20/2018Needham & Company LLCUpgradeHold -> Buy$30.89 -> $60.00HighView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$44.00LowView Rating Details
1/17/2018Leerink SwannReiterated RatingOutperform -> Positive$53.00 -> $56.00LowView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00LowView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
8/8/2016JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings History and Estimates Chart

Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings Estimates

2018 EPS Consensus Estimate: ($3.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.83)($0.83)($0.83)
Q4 20181($0.87)($0.87)($0.87)

Arena Pharmaceuticals (NASDAQ ARNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.68)N/AView Earnings Details
3/14/2018Q4 2017($0.65)($0.35)$5.75 million$15.40 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.66)($0.65)$5.48 million$7.95 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.74)($0.77)$5.58 million$6.49 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
5/1/2012Q1 2012($1.30)($1.54)ViewN/AView Earnings Details
3/14/2012Q4 2011($1.50)($1.62)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
11/9/2010Q3 2010($2.30)($3.09)ViewN/AView Earnings Details
8/3/2010Q2 2010($2.80)($2.76)ViewN/AView Earnings Details
5/7/2010Q1 2010($3.20)($3.30)ViewN/AView Earnings Details
3/12/2010Q4 2009($3.00)($3.76)ViewN/AView Earnings Details
11/9/2009Q3 2009($3.40)($3.83)ViewN/AView Earnings Details
8/3/2009Q2 2009($4.80)($4.80)ViewN/AView Earnings Details
5/11/2009Q1 2009($6.90)($6.82)ViewN/AView Earnings Details
3/12/2009Q4 2008($7.80)($8.44)ViewN/AView Earnings Details
10/30/2008Q3 2008($8.30)($7.60)ViewN/AView Earnings Details
8/5/2008Q2 2008($7.30)($8.92)ViewN/AView Earnings Details
5/7/2008Q1 2008($6.70)($7.47)ViewN/AView Earnings Details
2/27/2008Q4 2007($8.20)($5.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arena Pharmaceuticals (NASDAQ:ARNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 60.03%
Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Steven W SpectorEVPSell30,001$34.57$1,037,134.5734,691View SEC Filing  
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.0076,875View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.001,875View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.7285,529View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.0068,728View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.0082,876View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.0018,728View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.2568,728View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.0035,000View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00101,794View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00583,704View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00483,000View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arena Pharmaceuticals (NASDAQ ARNA) News Headlines

Source:
DateHeadline
$1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter$1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter
www.americanbankingnews.com - April 21 at 4:40 AM
Arena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at CitigroupArena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at Citigroup
www.americanbankingnews.com - April 20 at 3:01 PM
Arena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClubArena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM
Arena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment ResearchArena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 20 at 7:46 AM
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical TrialsQ2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials
seekingalpha.com - April 19 at 4:13 PM
 Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS
www.americanbankingnews.com - April 19 at 9:07 AM
Arena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in StockArena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in Stock
www.americanbankingnews.com - April 18 at 7:13 PM
Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from BrokeragesArena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 9:07 AM
Arena CEO: We have two great assets and are trying to bui...Arena CEO: We have two great assets and are trying to bui...
finance.yahoo.com - April 17 at 4:13 PM
Arena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngineArena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 17 at 11:05 AM
Arena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClubArena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 PM
Arena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short InterestArena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 14 at 1:40 AM
Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 13 at 4:08 PM
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual MeetingArena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
finance.yahoo.com - April 12 at 10:54 AM
This $3 Medical Device Stock be Worth $9-14 with Impending Product LaunchThis $3 Medical Device Stock be Worth $9-14 with Impending Product Launch
finance.yahoo.com - April 5 at 8:24 AM
 Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million
www.americanbankingnews.com - April 4 at 4:18 AM
Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per ShareArena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 2 at 7:22 AM
Arena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells FargoArena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells Fargo
www.americanbankingnews.com - March 31 at 12:12 AM
Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains ElusiveArena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive
finance.yahoo.com - March 29 at 4:01 PM
Arena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment ResearchArena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:45 PM
BidaskClub Lowers Arena Pharmaceuticals (ARNA) to BuyBidaskClub Lowers Arena Pharmaceuticals (ARNA) to Buy
www.americanbankingnews.com - March 28 at 11:56 AM
Arena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor FitzgeraldArena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 27 at 10:23 PM
Arena Pharmaceuticals (ARNA) "Positive" Rating Reaffirmed at Leerink SwannArena Pharmaceuticals' (ARNA) "Positive" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 27 at 6:16 PM
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional SharesArena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - March 27 at 10:12 AM
Arena Pharmaceuticals (ARNA) Upgraded at BidaskClubArena Pharmaceuticals (ARNA) Upgraded at BidaskClub
www.americanbankingnews.com - March 26 at 8:58 AM
Arena Pharmaceuticals (ARNA) Cut to Buy at BidaskClubArena Pharmaceuticals (ARNA) Cut to Buy at BidaskClub
www.americanbankingnews.com - March 25 at 12:50 AM
Citigroup Boosts Arena Pharmaceuticals (ARNA) Price Target to $55.00Citigroup Boosts Arena Pharmaceuticals (ARNA) Price Target to $55.00
www.americanbankingnews.com - March 24 at 9:28 PM
3 Biotech Stocks That Skyrocketed This Week: Are They Buys?3 Biotech Stocks That Skyrocketed This Week: Are They Buys?
finance.yahoo.com - March 24 at 4:28 PM
Arena Pharmaceuticals (ARNA) Downgraded by BidaskClub to SellArena Pharmaceuticals (ARNA) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 24 at 1:54 PM
Arena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by AnalystsArena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 24 at 8:29 AM
Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 - PR Newswire (press release)Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 - PR Newswire (press release)
www.prnewswire.com - March 24 at 8:10 AM
Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27
finance.yahoo.com - March 24 at 8:09 AM
Arena Pharmaceuticals (ARNA) Rating Increased to Hold at ValuEngineArena Pharmaceuticals (ARNA) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 23 at 11:22 PM
Arena Pharmaceuticals Takes Aim at CelgeneArena Pharmaceuticals Takes Aim at Celgene
finance.yahoo.com - March 23 at 6:24 PM
One Biotech Turnaround to WatchOne Biotech Turnaround to Watch
finance.yahoo.com - March 23 at 9:37 AM
Arena Raises Impressive $352 Million On Stock Offering - Seeking AlphaArena Raises Impressive $352 Million On Stock Offering - Seeking Alpha
seekingalpha.com - March 22 at 4:13 PM
Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% HigherArena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher
finance.yahoo.com - March 22 at 9:52 AM
Leerink Swann Weighs in on Arena Pharmaceuticals, Inc.s Q2 2018 Earnings (ARNA)Leerink Swann Weighs in on Arena Pharmaceuticals, Inc.'s Q2 2018 Earnings (ARNA)
www.americanbankingnews.com - March 22 at 9:34 AM
Traders Purchase High Volume of Arena Pharmaceuticals Put Options (ARNA)Traders Purchase High Volume of Arena Pharmaceuticals Put Options (ARNA)
www.americanbankingnews.com - March 22 at 7:16 AM
Here's Why Arena Pharmaceuticals, Inc. Surged Again on WednesdayHere's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday
finance.yahoo.com - March 21 at 4:14 PM
Arena Pharmaceuticals (ARNA) "Buy" Rating Reaffirmed at CitigroupArena Pharmaceuticals' (ARNA) "Buy" Rating Reaffirmed at Citigroup
www.americanbankingnews.com - March 21 at 1:56 PM
Heres Why Arena Pharmaceuticals Jumped 30% TodayHere's Why Arena Pharmaceuticals Jumped 30% Today
www.msn.com - March 21 at 10:50 AM
Arena Pharma (ARNA) to Offer 7.5M Shares of Common StockArena Pharma (ARNA) to Offer 7.5M Shares of Common Stock
www.streetinsider.com - March 21 at 10:50 AM
Arena Pharmaceuticals shares tick lower on secondary offeringArena Pharmaceuticals shares tick lower on secondary offering
www.marketwatch.com - March 21 at 10:50 AM
Arenas (ARNA) Etrasimod Meets Phase II Colitis Study GoalArena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
finance.yahoo.com - March 21 at 10:50 AM
Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI PharmaceuticalsToday’s Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals
finance.yahoo.com - March 21 at 10:50 AM
Arenas (ARNA) Etrasimod Meets Phase II Colitis Study Goal - NasdaqArena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal - Nasdaq
www.nasdaq.com - March 20 at 4:12 PM
ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch - NasdaqARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch - Nasdaq
www.nasdaq.com - March 20 at 4:12 PM
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock - PR Newswire (press release)Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:12 PM
Arena Pharma (ARNA) to Offer 7.5M Shares of Common Stock - StreetInsider.comArena Pharma (ARNA) to Offer 7.5M Shares of Common Stock - StreetInsider.com
www.streetinsider.com - March 20 at 4:12 PM

SEC Filings

Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.